JP2013533217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533217A5 JP2013533217A5 JP2013511302A JP2013511302A JP2013533217A5 JP 2013533217 A5 JP2013533217 A5 JP 2013533217A5 JP 2013511302 A JP2013511302 A JP 2013511302A JP 2013511302 A JP2013511302 A JP 2013511302A JP 2013533217 A5 JP2013533217 A5 JP 2013533217A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pegylated
- peptide
- neuropathy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 108010075254 C-Peptide Proteins 0.000 claims 14
- 230000007774 longterm Effects 0.000 claims 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 206010036105 Polyneuropathy Diseases 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 230000007824 polyneuropathy Effects 0.000 claims 4
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000005036 nerve Anatomy 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000019382 nerve compression syndrome Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010002652 Anorgasmia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019736 Cranial nerve disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 206010031127 Orthostatic hypotension Diseases 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010065427 Reflux nephropathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010040021 Sensory abnormalities Diseases 0.000 claims 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010005038 bladder diverticulum Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 201000005937 cranial nerve palsy Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34529310P | 2010-05-17 | 2010-05-17 | |
| US61/345,293 | 2010-05-17 | ||
| US201161448402P | 2011-03-02 | 2011-03-02 | |
| US61/448,402 | 2011-03-02 | ||
| PCT/US2011/036858 WO2011146518A2 (en) | 2010-05-17 | 2011-05-17 | Pegylated c-peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533217A JP2013533217A (ja) | 2013-08-22 |
| JP2013533217A5 true JP2013533217A5 (OSRAM) | 2014-07-03 |
Family
ID=44992295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511302A Pending JP2013533217A (ja) | 2010-05-17 | 2011-05-17 | Ｐｅｇ化ｃ−ペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8927488B2 (OSRAM) |
| EP (1) | EP2571896A4 (OSRAM) |
| JP (1) | JP2013533217A (OSRAM) |
| KR (1) | KR20130115086A (OSRAM) |
| CN (1) | CN103119055A (OSRAM) |
| CA (1) | CA2798518A1 (OSRAM) |
| MX (1) | MX2012013375A (OSRAM) |
| NZ (1) | NZ603399A (OSRAM) |
| WO (1) | WO2011146518A2 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| EP3372617B1 (en) * | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| MX2012013375A (es) | 2010-05-17 | 2013-04-11 | Cebix Inc | Peptido c pegilado. |
| ES2687651T3 (es) * | 2011-09-12 | 2018-10-26 | Amunix Operating Inc. | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos |
| EP2780030A4 (en) * | 2011-11-17 | 2015-11-18 | Cebix Ab | PEGYLATED C-PEPTIDE |
| US20130288973A1 (en) * | 2011-12-14 | 2013-10-31 | Edmund Burke | Decellularized small particle tissue |
| US9988433B2 (en) * | 2013-03-14 | 2018-06-05 | Mosaic Biosciences, Inc. | Covalent modification of biological macromolecules |
| WO2013116791A1 (en) | 2012-02-02 | 2013-08-08 | Mosaic Biosciences, Inc. | Biomaterials for delivery of blood extracts and methods of using same |
| US20150087586A1 (en) * | 2012-03-29 | 2015-03-26 | Cebix, Inc. | Pegylated c-peptide |
| US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
| BR122019026637B1 (pt) * | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| AU2014328458B2 (en) * | 2013-09-24 | 2020-03-12 | Allergan Pharmaceuticals International Limited | Method of extracting protein |
| RU2017131285A (ru) * | 2015-02-09 | 2019-03-11 | Мозеик Байосайенсиз, Инк. | Биоразлагаемые тиол-ен-полимеры и способы их получения |
| US10335492B2 (en) * | 2015-03-03 | 2019-07-02 | Nansha Biologics (Hong Kong) Limited | Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation |
| CA2979397A1 (en) | 2015-03-12 | 2016-09-15 | Board Of Trustees Of Michigan State University | Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases |
| SG10202008963QA (en) * | 2015-09-18 | 2020-10-29 | Univ Miyazaki | Long-acting adrenomedullin derivative |
| CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
| ES2894629T3 (es) | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| JP7058857B2 (ja) * | 2017-08-30 | 2022-04-25 | クラシエホームプロダクツ株式会社 | 毛髪タンパク質の水との相互作用測定方法 |
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| EP3687578B1 (en) * | 2017-09-28 | 2023-12-27 | The Regents of the University of California | Polyion complex polypeptide hydrogels and uses thereof |
| US11357861B2 (en) | 2017-09-29 | 2022-06-14 | Hanmi Pharm. Co., Ltd | Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor |
| EP4321220B1 (en) * | 2017-12-01 | 2025-10-29 | CSL Behring LLC | A1at for treating acute graft versus host disease after hematopoeitic cell transplantation |
| JPWO2019107566A1 (ja) | 2017-12-01 | 2020-12-03 | 株式会社ステムリム | 外胚葉性間葉系幹細胞およびその製造方法 |
| AU2019268410B2 (en) * | 2018-05-16 | 2025-01-02 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
| EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| CN113423466B (zh) * | 2018-10-25 | 2025-04-25 | 国立大学法人大阪大学 | 软骨病症的治疗剂 |
| BR112021008098A2 (pt) | 2018-11-15 | 2021-08-10 | Quantum-Si Incorporated | métodos e composições para o sequenciamento de proteínas |
| US20220177704A1 (en) * | 2019-03-27 | 2022-06-09 | The Regents Of Theuniversity Of California | Mixtures of synthetic copolypeptide hydrogels |
| CN113677736B (zh) * | 2019-03-29 | 2024-08-02 | 日油株式会社 | 分支型分解性聚乙二醇衍生物 |
| EP3950703A4 (en) | 2019-03-29 | 2023-01-04 | NOF Corporation | Branched degradable polyethylene glycol binder |
| CN111939244B (zh) * | 2019-05-14 | 2024-08-06 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| KR102456958B1 (ko) | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| US12090206B2 (en) | 2020-04-23 | 2024-09-17 | The Regents Of The University Of California | Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels |
| WO2021236983A2 (en) * | 2020-05-20 | 2021-11-25 | Quantum-Si Incorporated | Methods and compositions for protein sequencing |
| CN114137094A (zh) * | 2020-09-03 | 2022-03-04 | 北京渼颜空间生物医药有限公司 | 一种聚左旋乳酸中有关物质的检测方法 |
| US20220401525A1 (en) * | 2021-06-16 | 2022-12-22 | Biocell Technology, Llc | Use of collagen compositions for increasing telomere length |
| CN116554267A (zh) * | 2022-01-30 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇修饰的激肽或其变体和药物应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW17482A1 (en) * | 1981-08-27 | 1982-11-17 | Lilly Co Eli | Pharmaceutical formulations comprising human insulin and human c-peptide |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| FR2686759B1 (fr) | 1992-01-29 | 1994-04-22 | Sgs Thomson Microelectronics | Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie . |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| SE520392C2 (sv) | 1996-09-27 | 2003-07-01 | Creative Peptides Sweden Ab C | Specifika peptider för behandling av diabetes mellitus |
| US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| ES2222689T3 (es) | 1998-03-12 | 2005-02-01 | Nektar Therapeutics Al, Corporation | Derivados del polietilenglicol con grupos reactivos proximales. |
| DK1140145T4 (da) * | 1999-01-14 | 2019-07-22 | Amylin Pharmaceuticals Llc | Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf |
| US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| DK1259562T3 (da) | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| GB0022342D0 (en) | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| DE10055742B4 (de) | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US7265186B2 (en) | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| ATE446971T1 (de) | 2001-09-07 | 2009-11-15 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese |
| US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| JP4758608B2 (ja) * | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| RS53104A (sr) * | 2001-11-20 | 2006-10-27 | Pharmacia Corporation | Hemijski modifikovani konjugati humanog hormona rasta |
| GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
| JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| PT2644206T (pt) | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
| US20050074425A1 (en) | 2003-07-02 | 2005-04-07 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| KR20120073370A (ko) * | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| CA2563176A1 (en) * | 2004-04-22 | 2005-11-10 | Regado Biosciences, Inc. | Improved modulators of coagulation factors |
| WO2005108463A2 (en) | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Branched polyethylen glycol derivates comprising an acetal or ketal branching point |
| US9085659B2 (en) | 2004-05-03 | 2015-07-21 | Nektar Therapeutics | Polymer derivatives comprising an imide branching point |
| GB0412174D0 (en) * | 2004-06-01 | 2004-06-30 | Creative Peptides Sweden Ab | Degradation-resistant analogues of pro-insulin c-peptide |
| EP1850878A2 (en) * | 2005-02-10 | 2007-11-07 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| ATE524509T1 (de) | 2005-07-18 | 2011-09-15 | Nektar Therapeutics | Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen |
| GB0601950D0 (en) | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
| JP4261531B2 (ja) | 2005-09-06 | 2009-04-30 | 株式会社Ｎｒｌファーマ | ラクトフェリン複合体及びその製造方法 |
| KR101400105B1 (ko) * | 2006-07-25 | 2014-06-19 | 리폭센 테크놀로지즈 리미티드 | Ｎ-말단 폴리시알화 |
| JP5550338B2 (ja) * | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| RU2007137048A (ru) * | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете |
| WO2009117410A2 (en) | 2008-03-17 | 2009-09-24 | Board Of Regents, The University Of Texas System | Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques |
| US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| WO2010033240A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| US20110190192A1 (en) | 2009-12-15 | 2011-08-04 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| MX2012013375A (es) | 2010-05-17 | 2013-04-11 | Cebix Inc | Peptido c pegilado. |
-
2011
- 2011-05-17 MX MX2012013375A patent/MX2012013375A/es not_active Application Discontinuation
- 2011-05-17 US US13/109,522 patent/US8927488B2/en not_active Expired - Fee Related
- 2011-05-17 NZ NZ603399A patent/NZ603399A/en not_active IP Right Cessation
- 2011-05-17 EP EP11784109.8A patent/EP2571896A4/en not_active Withdrawn
- 2011-05-17 WO PCT/US2011/036858 patent/WO2011146518A2/en not_active Ceased
- 2011-05-17 CN CN2011800350917A patent/CN103119055A/zh active Pending
- 2011-05-17 JP JP2013511302A patent/JP2013533217A/ja active Pending
- 2011-05-17 KR KR1020127031723A patent/KR20130115086A/ko not_active Withdrawn
- 2011-05-17 CA CA2798518A patent/CA2798518A1/en not_active Abandoned
-
2012
- 2012-05-04 US US13/463,887 patent/US8691755B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533217A5 (OSRAM) | ||
| SI3072525T1 (en) | Procedures for lowering the levels of basophiles | |
| US7060708B2 (en) | Active agent delivery systems and methods for protecting and administering active agents | |
| JP7189133B2 (ja) | 徐放ｃｎｐ作動薬を用いた併用療法 | |
| EP3237014B1 (en) | Novel polymeric hgh prodrugs | |
| US20200061165A1 (en) | Methods and compositions for modulating the immune system with arginase i | |
| JP2015508774A5 (OSRAM) | ||
| JP2018535948A5 (OSRAM) | ||
| JP2010202664A5 (OSRAM) | ||
| JP2013510169A5 (OSRAM) | ||
| RU2013108857A (ru) | Соединения для лечения/профилактики воспалительных глазных заболевний | |
| JP2014526441A5 (OSRAM) | ||
| JP2013500253A (ja) | ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマー性複合体と組み合わせたｈｅｒ２受容体拮抗薬を用いるｈｅｒ２陽性がんの治療方法 | |
| IL278970B1 (en) | CNP drug meters | |
| MX2009007087A (es) | Metodos para la administracion de vacunas. | |
| RU2013123266A (ru) | Стабильные и растворимые антитела | |
| EP1758998A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES | |
| KR102156324B1 (ko) | 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물 | |
| RU2019109154A (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ДЕФИЦИТА ГОРМОНА РОСТА, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК hGH | |
| US20220372493A1 (en) | Rna nanoparticle for liver cancer treatment | |
| RU2013157928A (ru) | Терапевтические средства для регуляции уровня фосфора в сыворотке | |
| JP5973455B2 (ja) | 脱髄疾患の治療薬及び予防薬 | |
| JP2017536397A (ja) | 線維症の治療方法 | |
| US20170233737A1 (en) | Means and Methods for the Treatment of Nephropathy | |
| EP3939581A1 (en) | Estrogen receptor ligands, compositions and methods related thereto |